Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Long-Term Deferred Tax (2020 - 2023)

Historic Long-Term Deferred Tax for Lipocine (LPCN) over the last 4 years, with Q4 2023 value amounting to $47.8 million.

  • Lipocine's Long-Term Deferred Tax rose 412.99% to $47.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $47.8 million, marking a year-over-year increase of 412.99%. This contributed to the annual value of $47.8 million for FY2023, which is 412.99% up from last year.
  • According to the latest figures from Q4 2023, Lipocine's Long-Term Deferred Tax is $47.8 million, which was up 412.99% from $45.9 million recorded in Q4 2022.
  • In the past 5 years, Lipocine's Long-Term Deferred Tax ranged from a high of $47.8 million in Q4 2023 and a low of $36000.0 during Q4 2020
  • Moreover, its 4-year median value for Long-Term Deferred Tax was $44.4 million (2021), whereas its average is $34.2 million.
  • As far as peak fluctuations go, Lipocine's Long-Term Deferred Tax surged by 11940057.22% in 2021, and later soared by 412.99% in 2023.
  • Lipocine's Long-Term Deferred Tax (Quarter) stood at $36000.0 in 2020, then soared by 119400.57% to $43.0 million in 2021, then grew by 6.62% to $45.9 million in 2022, then increased by 4.13% to $47.8 million in 2023.
  • Its Long-Term Deferred Tax was $47.8 million in Q4 2023, compared to $45.9 million in Q4 2022 and $43.0 million in Q4 2021.